WuXi XDC Cayman Past Earnings Performance
Past criteria checks 5/6
WuXi XDC Cayman has been growing earnings at an average annual rate of 56.2%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 69% per year. WuXi XDC Cayman's return on equity is 9.9%, and it has net margins of 21.3%.
Key information
56.2%
Earnings growth rate
48.6%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | 69.0% |
| Return on equity | 9.9% |
| Net Margin | 21.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How WuXi XDC Cayman makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 2,796 | 595 | 196 | 95 |
| 31 Mar 24 | 2,460 | 439 | 156 | 86 |
| 31 Dec 23 | 2,124 | 284 | 117 | 77 |
| 30 Sep 23 | 1,889 | 259 | 113 | 65 |
| 30 Jun 23 | 1,654 | 235 | 109 | 53 |
| 31 Mar 23 | 1,322 | 195 | 105 | 43 |
| 31 Dec 22 | 990 | 156 | 101 | 34 |
| 31 Dec 21 | 311 | 55 | 40 | 14 |
| 31 Dec 20 | 96 | 26 | 10 | 4 |
Quality Earnings: L74 has high quality earnings.
Growing Profit Margin: L74's current net profit margins (21.3%) are higher than last year (14.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: L74's earnings have grown significantly by 56.2% per year over the past 5 years.
Accelerating Growth: L74's earnings growth over the past year (153.3%) exceeds its 5-year average (56.2% per year).
Earnings vs Industry: L74 earnings growth over the past year (153.3%) exceeded the Life Sciences industry -9.9%.
Return on Equity
High ROE: L74's Return on Equity (9.9%) is considered low.